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A B S T R A C T   
Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/ 
STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors 
that efficiently target BCR-ABL1 activity. However, drug resistance and intolerance are still therapeutic limita-
tions in Ph+ cells. Therefore, the development of new anti-CML drugs that exhibit alternative mechanisms to 
overcome these limitations is a desirable goal. In this work, the antitumoral activity of JKST6, a naphthoquinone- 
pyrone hybrid, was assessed in imatinib-sensitive and imatinib-resistant human CML cells. Live-cell imaging 
analysis revealed JKST6 potent antiproliferative activity in 2D and 3D CML cultures. JKST6 provoked cell in-
crease in the subG1 phase along with a reduction in the G0/G1 phase and altered the expression of key proteins 
involved in the control of mitosis and DNA damage. Rapid increases in Annexin V staining and activation/ 
cleavage of caspases 8, 9 and 3 were observed after JKST6 treatment in CML cells. Of interest, JKST6 inhibited 
BCR-ABL1/STAT5 signaling through oncokinase downregulation that was preceded by rapid polyubiquitination. 
In addition, JKST6 caused a transient increase in JNK and AKT phosphorylation, whereas the phosphorylation of 
P38-MAPK and Src was reduced. Combinatory treatment unveiled synergistic effects between imatinib and 
JKST6. Notably, JKST6 maintained its antitumor efficacy in BCR-ABL1-T315I-positive cells and CML cells that 
overexpress BCR-ABL and even restored imatinib efficacy after a short exposure time. These findings, together 
with the observed low toxicity of JKST6, reveal a novel multikinase modulator that might overcome the limi-
tations of BCR-ABL1 inhibitors in CML therapy.   
1. Introduction 
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell 
disease associated with abnormal proliferation of clonal cells of the 
myelogenous lineage [1]. This malignant myeloproliferative disorder is 
characterized by a chromosomal translocation t(9;22)(q34;q11) that 
provokes Philadelphia (Ph) chromosome emergence, a hallmark present 
in 95% of CML cases but also at lower frequencies in acute lymphoblastic 
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leukemia (ALL) and acute myeloid leukemia (AML) [2]. The resulting 
fused genes of the Ph chromosome encode the BCR-ABL1 oncogenic 
protein, whose constitutively active tyrosine kinase represents the 
keystone of CML pathogenesis [3]. BCR-ABL1 activates different intra-
cellular signaling pathways, including RAS/RAF/MAPK, PI3K/AKT and 
JAK/STAT, which are involved in the control of cell survival and pro-
liferation, among other key cellular responses [4]. Dysregulation of 
JAK/STAT signaling is indeed a common factor in hematological can-
cers, particularly in CML, where BCR-ABL1 can directly and indirectly 
activate STAT5, resulting in the overexpression of proto-oncogenic 
target genes (e.g., MYC and PIM1) [4,5]. Thus, BCR-ABL1/STAT5 
signaling triggers enhanced proliferation of CML clones and genomic 
instability, sustaining the conditions for a tumoral environment [6,7]. 
Given the above findings, it is not surprising that targeting BCR-ABL1 
has marked a milestone in the treatment of CML. 
In 2001, the Food and Drug Administration (FDA) approved the first 
tyrosine kinase inhibitor (TKI), imatinib mesylate (IM), which binds the 
BCR-ABL1 catalytic domain, blocking its activation [8]. Twenty years 
later, a broader spectrum of TKIs is available as first-line treatment for 
CML [9], allowing most early diagnosed CML patients to reach a 
near-normal life expectancy. However, TKIs exhibit key limitations in 
CML therapy, including some serious side effects mainly associated with 
second-generation TKIs, the emergence of TKI resistance, and the 
requirement for long-term medication, which triggers high economic 
costs [9,10]. Approximately 30–50% of CML patients discontinue IM 
therapy after 5 years, mainly due to the emergence of treatment resis-
tance (15–20%) and intolerance (5–7%) [11]. Hence, mechanisms 
involved in the generation of IM resistance have been extensively 
investigated. Interestingly, some are defined as BCR-ABL1-dependent 
mechanisms (e.g., augmented expression of the BCR-ABL1 gene or mu-
tations affecting the kinase domain of BCR-ABL1 that dodge TKI bind-
ing, such as T315I) [12], whereas others are categorized as 
BCR-ABL1-independent processes (e.g., alterations of efflux influx 
pumps, quiescent CML stem cell persistence, additional chromosomal 
abnormalities emergence or SRC family tyrosine kinases over-
expression) [8,12,13]. 
Regarding BCR-ABL1-dependent TKI resistance, it has been demon-
strated that the expression levels of the oncoprotein are unaltered with 
the inhibition of its kinase activity. Consequently, CML patients 
receiving TKI therapy normally need continuous treatment. Moreover, 
BCR-ABL1 can act as a scaffold protein, establishing signaling networks 
that are modified but not blocked by TKIs [14,15]. For these reasons, 
compounds able to reduce not only kinase activity but also the levels of 
the oncoprotein itself may represent an effective alternative therapy for 
CML. Importantly, the potential relevance of this alternative pharma-
cological strategy has recently been reinforced by the advent of PRO-
TACs (proteolysis targeting chimeras), which employ the 
ubiquitin-mediated degradation system to target oncogenic proteins 
[16], or the use of CRISPR (clustered regularly interspaced short 
palindromic repeats) technology to provide permanent oncogene 
knockout [17] in CML models. 
BCR-ABL1-independent IM resistance is associated with increased 
alternative survival signaling pathways (e.g., RAF/MEK/ERK) that 
confer apoptosis protection [18]. In this sense, preclinical and clinical 
studies have suggested that the combination of TKIs with multikinase 
inhibitors might be an attractive alternative to selective TKIs alone. 
Considering all these insights, identifying alternative drugs that over-
come the main limitations of current CML treatments is an important 
goal to be achieved by the cancer research community. 
Chemical structures based on natural products are widely utilized in 
drug discovery. In this study, we focused on naphthoquinones (NPQ), a 
chemical core with numerous medicinal properties (e.g., antibacterial, 
antifungal, antiviral, anti-inflammatory, antiparasitic or antitumoral) 
[19]. At present, quinone derivatives are commonly used in the clinic to 
treat solid tumors (e.g., doxorubicin) or hematological disorders (e.g., 
daunorubicin). Additionally, new NPQ-based compounds are being 
investigated in preclinical contexts with promising results in several 
types of malignancies (e.g., hepatocarcinoma, melanoma, leukemia, 
lung cancer, breast cancer or prostate cancer) [20]. In this regard, we 
have previously described original NPQ derivatives [21] and 
NPQ-hybrid compounds [22] that exhibited effective in vitro and in vivo 
anti-CML properties and that have contributed to the chemical design of 
the compound of this study, a novel NPQ-pyrone hybrid. Pyrones have 
also been described to exert strong cytotoxic activity against leukemic 
and ovarian cancer cells [23], reduce the viability of prostate cancer 
cells [24] or even sensitize tamoxifen-resistant breast cancer cells [25]. 
Therefore, the chemical structure of NPQ-pyrone represents a promising 
candidate to investigate its associated antitumor mechanisms. 
Herein, the present work investigates the pharmacological efficacy 
and molecular mechanisms involved in the action of a new NPQ-pyrone 
hybrid compound, 7-(3,4-dimethoxyphenyl)− 10-methylbenzo[h]pyr-
ano[4,3-b] chromene-5,6,8(7 H)-trione, named JKST6, in the context of 
CML. This study pays special attention to combinatorial therapy with IM 
and overcoming TKI resistance. Taken together, these findings provide a 
novel opportunity to find a drug strategy with a wider therapeutic 
window. 
2. Materials and methods 
2.1. Reagents 
Imatinib (IM) and Caspases 9, 8 and 3 substrates were purchased 
from Calbiochem (San Diego, USA). Murine IL-3 and human IL-6 were 
supplied by Miltenyi Biotec (Gladbach, Germany). Z-Leu-Leu-Leu-al 
proteasome inhibitor was purchased from Merck (Darmstadt, Germany). 
In most cases, other reagents used in this research were procured by 
Promega (Wisconsin, USA), Roche Biochemicals (Mannheim, Germany), 
Sigma–Aldrich or Merck (Darmstadt, Germany). 
2.2. Synthesis of JKST6 
A mixture of 30 mg of 2-hydroxy-1,4-naphthoquinone (0.17 mmol), 
54.7 mg of 3,4-dimethoxybenzaldehyde (0.34 mmol), and 42.9 mg of 4- 
hydroxy-6-methyl-2H-pyran-2-one (0.34 mmol) was ground for 5 min, 
16.4 mg (30 mol%) of BiCl3 was added, and the reaction mixture was 
ground again for 15 min. After incubation for 4 h at 120 ◦C, the resulting 
crude material was purified by preparative TLC using 1% DCM/MeOH as 
the eluent to provide 30.7 mg (42%) of JKST-6 as an amorphous orange 
solid. Mp: 251.3–252.5 ◦C. 1H NMR (500 MHz, CDCl3) δ 2.31 (s, 3 H), 
3.79 (s, 3H), 3.90 (s, 3H), 4.99 (s, 1H), 6.19 (s, 1H), 6.72 (d, J=8.3 Hz, 
1H), 6.75 (d, J=1.5, 8.3 Hz, 1H), 7.11 (s, 1H), 7.61 (t, J=7.4 Hz, 1H), 
7.78 (t, J=7.8 Hz, 1H),7.95 (d, J=7.8 Hz, 1H), 8.13 (d, J=7.6 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 20.1 (CH3), 32.6 (CH), 55.9 (CH3), 56.0 
(CH3), 98.0 (CH), 103.4 (C), 111.2 (CH), 113.0 (CH), 117.4 (C), 119.9 
(CH), 124.3 (CH), 129.8 (C), 129.9 (C), 130.0 (CH), 131.6 (CH), 134.2 
(C), 135.3 (CH), 148.4 (C), 148.8 (C), 155.4 (C), 157.9 (C), 162.0 (C), 
162.5 (C), 177.4 (C), 178.1 (C); EIMS m/z (%): 430 ([M+], 100), 399 
(28), 343 (34), 293 (70). HREIMS: 430.1053 (calc. for C25H18O7 [M+] 
430.1053). 
2.3. Cells 
Cell lines used in the in vitro experiments were purchased from the 
American Type Culture Collection (ATCC). Human hematologic cell 
lines were grown in RPMI-1640 cell culture medium: IM-sensitive 
chronic myelogenous leukemia (CML) (K562, K562-GFP+, AR230); 
IM-resistant CML (K562-R [21], AR230-R); erythroleukemia (HEL); 
acute promyelocytic leukemia (HL60), acute monocytic leukemia 
(MOLM.13, MV4.11) and acute T cell leukemia (JURKAT). The human 
nonhematologic cell lines triple negative breast cancer (BT-549, 
MDA-MB-231, HS-578T), ER+ breast cancer (MCF7), HER2+ breast 
cancer (SKBR3) and endometrial adenocarcinoma (Ishikawa) were 
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maintained in different media. BT-549 cells were grown in RPMI-1640 
medium. MDA-MB-231 and HS-578T cells were maintained in DMEM. 
SKBR3 cells were grown in McCoýs 5 A medium. Ishikawa cells were 
grown in MEM. Human peripheral blood mononuclear cells (PBMCs) 
were isolated from the heparin-anticoagulated blood of healthy volun-
teers by density gradient centrifugation with Ficoll-Paque™ PLUS (GE 
Healthcare Bio-Sciences AB, Sweden) and cultured in RPMI-1640 me-
dium. Monkey nonmalignant kidney cells (Vero) and mouse monocyte 
macrophages (RAW 264.7) were grown in DMEM. Human mesenchymal 
stem cells (hMSC-TERT), kindly provided by Dr. J. M. Zapata [26], were 
maintained in low-glucose DMEM supplemented with 10% heat inacti-
vated FBS. Genetically engineered KmycBT315I cells were generated by 
Dr. J. León [27]. Cell culture media were supplemented with 10% FBS, 
L-glutamine (2 mM) and PEST (50 units/ml penicillin, 50 μg/ml strep-
tomycin), and when indicated for BT-549 cells, medium was further 
supplemented with 1 mM NaPyr and 10 mM HEPES. Cell culture media 
(RPMI-1640, DMEM) and supplements (FBS, L-glutamine, PEST) were 
purchased from Biowest (Nuaillé, France). 
2.4. Cell viability assays 
Immortalized cells were seeded at exponential growth density (5000 
– 10,000 cells per well) in 96-well plates (BD Falcon, France), whereas 
PBMCs were seeded at 100,000 cells per well. Cells were treated with 
vehicle (0.05% DMSO) or test compounds (0.01–30 µM) for 24–72 h. 
Then, the tetrazolium salt 3-(4,5-methyltiazol-2yl-)− 2,5diphenyl- 
tetrazolium bromide (MTT) (Applichen, Germany) was added to cells, 
incubated for 2–4 h at 37 ◦C, and lysed in 10% SDS, and the optical 
density was measured at 595 nm with an iMark Microplate Reader 
(Bio–Rad, CA, USA) to determine the mitochondrial metabolization of 
the tetrazolium salt [28]. 
2.5. Wash-out assays 
Cells were seeded at exponential growth (10,000 cells per well) in a 
96-well plate (BD Falcon, France) and then treated with vehicle (0.05% 
DMSO), IM (0.03–5 µM), doxorubicin (0.1–10 µM) or JKST6 (0.1–10 
µM) for 3 h. Then, drugs were removed after thorough washing with 
medium at 37 ◦C, and cells were left in drug-free medium for 48 h until 
cell viability was evaluated using the MTT assay [28]. 
2.6. Real-time monitoring of tumor growth (2D and 3D assays) 
First, for 2D assays, CML cell lines were seeded at 5000 cells per well 
in a poly-L-lysine-coated 96-well plate (BD Falcon, France). Once the 
cell monolayer was stable after 16 h, it was treated with vehicle (0.05% 
DMSO) or test compound (0.03–10 µM). YOYO-1 (25 nM) (Invitrogen) 
was used to monitor cell membrane integrity [22]. Cell proliferation and 
viability were analyzed using microphotographs taken by an IncuCyte™ 
HD real-time imaging system (Essen BioScience, UK). The effects of each 
compound dose on cell growth and membrane integrity were monitored 
for 5 days. Then, area under the curve (AUC) values were plotted to 
analyze both the kinetics and dose effects on cell proliferation (IC50) 
and cytotoxicity (EC50). To support 2D assays, the effect of drugs on cell 
spheroids was also studied by seeding 3000 cells per well in 
round-bottomed, ultralow attachment, 96-well plates (ULA, Corning) 
[29]. Next, 24 h after spheroid formation, cells were treated with vehicle 
(0.05% DMSO) or drugs. The volume size and cytotoxicity of spheroids 
were recorded for 5 days. To calculate spheroid volume, confluence 
measurements were extracted using two different metrics: average 
phase object area (µm2) and object count (1/image). These metrics were 
multiplied to obtain the total object area (µm2), which was further used 
to calculate the spheroid radius (r = √Total Object Area/π) and the 
spheroid volume (µm3) (V = 4/3 πr3) [29]. 
2.7. Luciferase reporter gene assay 
The potential effects of drugs on STAT3 and STAT5-mediated tran-
scriptional activity were evaluated using the Renilla Luciferase Reporter 
cell lines (Leeporter™ Abeomics) HEK293 and Ba/F3, respectively. Cells 
were seeded at 500,000 cells per well in a 12-well culture plate and 
600,000 cells per well in a 24-well culture plate each. Vehicle (0.05% 
DMSO) or compounds (0.3–10 µM) were added before stimulation of 
Ba/F3 and HEK293 cells with 30 ng/ml murine IL3 (mIL3) or 10 ng/ml 
human IL6 (hIL6), respectively. Cells were lysed in Passive Lysis Buffer 
(Promega, USA), and luciferase activity was determined using a Renilla- 
Firefly Luciferase Assay kit (Thermo Scientific, USA) in a microplate 
reader (Clarity™ R2, BioTek). The results are expressed as relative 
luciferase units (RLUs) per mg of protein and were normalized to the 
results obtained in vehicle-treated cells. In parallel, MTT assays were 
carried out to investigate the effects of the compounds on the viability of 
the reporter cell lines. 
2.8. Cell cycle and apoptosis analysis 
For cell cycle studies, unsynchronized K562 cells were seeded at 
300,000 cells/well in 6–well plates and treated with vehicle (0.05% 
DMSO) or JKST6 for 12, 24 and 48 h. After treatment, cells were har-
vested, washed in PBS, and fixed overnight in cold 70% ethanol. Then, 
the cells were resuspended in PBS containing DNAse-free RNAse 
(500 μg/ml) for 2 h at 37 ◦C, incubated with propidium iodide (PI) 
(5 μg/ml), and analyzed in an Accuri C6 flow cytometer (BD). A FITC- 
Annexin V Apoptosis Detection Kit I (BD Biosciences) was used for cell 
death analysis. Briefly, cells were resuspended in 100 μl of ice-cold 
binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), 
containing 5 μl of Annexin V FITC and 5 μl of PI (50 μg/ml), incubated 
for 15 min at room temperature, and finally, binding buffer (400 μl) was 
added. In both experiments, 50,000 events were collected and analyzed 
by fluorescence-activated cell sorting (FACS). Early apoptosis was also 
assessed using bisBenzimide Hoechst 33258 (Sigma–Aldrich, USA), and 
microphotographs were used to count the proportion of apoptotic nuclei 
per total nuclei observed. 
2.9. Caspase activity assay 
K562 cells were seeded at 250,000 cells/ml in 100-mm cell culture 
dishes and treated with vehicle (0.05% DMSO) or JKST6 (2 µM) for 6, 12 
and 24 h or etoposide (30 µM) for 24 h. Next, cell pellets were resus-
pended in lysis buffer (50 mM HEPES, pH 7.4, 1 mM dithiothreitol, 
0.1 mM EDTA, 0.1% Chaps, aprotinin, and PMSF) and centrifuged, and 
supernatants were utilized for the enzymatic assays. Specific peptides 
that are known substrates for caspase-3, − 8, and − 9 activities include N- 
acetyl-Asp-Glu-Val-Asp-p-nitroaniline (DEVDpNA), N-acetyl-Ile-Glu- 
Thr-Asp-p-nitroaniline (IETD-pNA), and N-acetyl-Leu-Glu-His-Asp-p- 
nitroaniline (LEHD-pNA) (Calbiochem, San Diego, CA), respectively. 
Caspase substrate cleavage leads to p-nitroaniline (pNA) release, which 
in turn increases its 405-nm absorbance proportionally to caspase ac-
tivity. The results are expressed as the absorbance at 405 nm per mg of 
protein normalized to vehicle (0.05% DMSO)-treated cells. 
2.10. Immunoblotting 
Cells were seeded at 300,000 cells/ml in 100-mm dishes and treated 
with vehicle (0.05% DMSO) or compounds for the times and doses 
indicated in the figure legends. Cells were washed with cold PBS- 
ortovanadate (1 mM), centrifuged, and resuspended in RIPA buffer 
(Thermo Fisher Scientific, USA) with protease and phosphatase in-
hibitors (Thermo Fisher Scientific, USA). Cell lysis was achieved with 
30 min of gentle agitation at 4 ◦C. Lysates were then centrifuged, and 
supernatants were collected. Protein amount was measured using a 
bicinchoninic acid assay (BCA) kit (BioRad). Equal protein amounts 
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were analyzed by SDS–PAGE and transferred to nitrocellulose mem-
branes (Thermo Fisher Scientific, USA). Then, 5% BSA-(anti-phospho- 
antibodies) (Merck, Darmstadt, Germany) or 5% blotto (anti-total an-
tibodies) (Merck, Darmstadt, Germany) diluted in Tris-buffered saline 
containing 0.05% Tween 20 (TBS-T) was used to block membranes for 
1–2 h. Membranes were incubated overnight at 4 ºC with the following 
primary antibodies: pTyr694STAT5 (pSTAT5Y694), STAT5, pTyr705-
STAT3 (pSTAT3Y705), STAT3, pTyr177BCR (pBCR-ABL1Y177/pBCRY177), 
BCR, pTyr412ABL (pBCR-ABL1Y412), ABL, pThr183/Tyr185JNK 
(pJNKT183/Y185), pSer473AKT (pAKTS473), pThr308AKT (pAKTT308), AKT, 
pThr202/pTyr204ERK1/2 (pERK1/2T202/Y204), ERK1/2, pTyr207CrkL 
(pCrkLY207), CrkL, pSer240/244S6 (pS6S240/244), S6, PIM1, pSer780pRB 
(pRBS780), pSer807/811pRB (pRBS807/S811), cyclin E, pTyr15CDK1 
(pCDK1Y15), pSer642Wee1 (pWee1S642), Wee1, p27, p21, pSer296Chk1 
(pChk1S296), pThr68Chk2 (pChk2T68), caspase-8, caspase-9, caspase-3 
and γH2AX, which were purchased from Cell Signaling Technology 
(Leiden, The Netherlands). Antibodies to detect β-actin, JNK1/3 (C-17), 
c-MYC, cyclin B, Mcl-1 and calnexin were purchased from Santa Cruz 
Biotech (CA, USA). Cyclin A and BUBR1 were provided by BD Trans-
duction Laboratories. Polyubiquitin and pSer10 H3 (pH 3S10) antibodies 
were provided by EMD Millipore. After washing with TBS-T, membranes 
were incubated with horseradish peroxidase-conjugated secondary an-
tibodies (goat anti-rabbit and goat anti-mouse) that were obtained from 
Bio–Rad (CA, USA) for 1 h at room temperature. Finally, the protein 
bands were visualized using Clarity™ Western ECL Substrate (Bio–Rad, 
CA, USA) in the ChemiDoc XRS system (Bio–Rad, CA, USA) and were 
analyzed with Quantity One software (Bio–Rad, CA, USA). 
2.11. Real-time PCR 
Cells were seeded at 300,000 cells/ml in 100-mm dishes and treated 
with vehicle (0.05% DMSO), JKST6 (3 µM) or IM (1 µM) for 1, 3, 6 and 
12 h. Then, the cells were harvested, and total RNA was isolated using 
PureZOL RNA Isolation Reagent (Bio–Rad, CA, USA). RNA concentra-
tion and acid nucleic purity were measured with a NanoDrop 1000 
spectrophotometer (Wilmington, USA). Then, 1 µg of total RNA was 
used for reverse transcription to cDNA with the iScript™ kit (Bio–Rad, 
CA, USA) following the manufactureŕs protocol. Real-time quantitative 
PCR (qPCR) was performed using SYBR Green PCR Master mix (Applied 
Biosystems, Massachusetts, USA). Exon-specific primers (Table 1) [30] 
were purchased from STAB VIDA (Caparica, Portugal). Gene expression 
was analyzed with an Mx3005P qPCR System (Agilent, CA, USA). The 
cycle threshold values were determined using MxPro qPCR Software 
(Agilent, CA, USA), and target gene expression was normalized to the 
GAPDH housekeeping gene. All amplifications were performed in 
duplicate, and Ct scores were averaged for subsequent calculations of 
relative expression values according to the comparative CT method for 
qPCR [31]. 
2.12. Drug combination assays 
K562-GFP+ cells were seeded at 5000 cells per well in a 96-well plate 
(BD Falcon, France), and cell proliferation was analyzed using micro-
photographs in an IncuCyte™ HD real-time imaging system (Essen 
BioScience, UK). Briefly, cells were exposed to constant ratio combina-
tions of JKST6 with IM by doubling dilutions of the individual drugs 
over a wide range of concentrations. Inhibition of cell proliferation, 
relative to untreated controls, was assigned as the effect and ranged 
from 0 (no cell proliferation inhibition) to 1 (100% cell proliferation 
inhibition). Dose-effect curves of single or combined drug treatments 
were plotted and analyzed by the median effect method of Chou and 
Talalay [32] using Calcusyn software 2.0 (Biosoft, Cambridge, UK). The 
analysis generated the combination index (CI) values. CI values less than 
1, equal to 1, and greater than 1 indicated synergism, addition, and 
antagonism, respectively. 
2.13. Acute and subchronic toxicity in vivo 
Acute and subchronic studies were approved by the Bioethics Com-
mittee of University of La Laguna (CEIBA 2018–0291) and the Univer-
sity of Las Palmas de Gran Canaria (OEBA-44/2019R1), respectively. 
The experiments were performed according to OECD guidelines for the 
testing of chemicals (N◦ 407; 452). The Irwin test [33] was performed in 
FVB male mice (Charles River Code: 207) to investigate intraperitoneal 
(i.p.) and oral JKST6 acute toxicity. Briefly, 12 mice were randomly 
distributed into 4 groups of treatments: 1) i.p. treated with vehicle 
(dimethilsulfoxide (DMSO): PEG400: saline; 10:40:50); 2) i.p. treated 
with JKST6 (10 mg/kg); 3) orally administered vehicle (DMSO: meth-
ylcellulose 0.5% (MC); 10:90); and 4) orally treated with JKST6 
(50 mg/kg). Animals were treated each day for 5 consecutive days. 
Every day after treatment, clinical signs were gathered by two inde-
pendent researchers. After 5 days, animals were euthanized by carbon 
dioxide overdose, necropsy allowed us to explore morphological 
changes in organs (liver, spleen, kidney), and every organ weight was 
normalized by animal body weight. The subchronic toxicity assay was 
performed in BALB/c (Charles River code: 028) male (n = 10) and fe-
male (n = 10) mice for 30 days. Vehicle (DMSO: PEG400: saline; 
10:40:50) or JKST6 (10 mg/kg) was i.p. administered every two days. 
Animal welfare was assessed daily to detect any clinical signs. Body 
weight and food and water consumption were tracked every day of 
treatment. Body composition (lean, fat and fluid) was determined using 
an MRI scan (Bruker Minispec, Massachusetts, USA). At Day 30, mice 
were euthanized by isoflurane overdose followed by necropsy analysis. 
Blood cell counting (MS4–5, Melet Schloesing, Osny, France) and 
biochemistry analyses (Pointcare v2, Mano Médical, France) were also 
performed. 
2.14. Statistical analysis 
The data shown are the results of two to six independent experiments 
with at least three replicates per experimental condition. The results are 
expressed as the mean ± standard error of the mean (SEM) or as the 
mean ± standard deviation (SD) in the in vitro and in vivo assays, 
respectively. Differences between means of two groups were analyzed 
with two-tailed Student’s t-test. One-way ANOVA followed by Bonfer-
roni post hoc test was used to compare means from more than two 
groups using GraphPad Prism 8.3.0 Software (CA, USA). Statistical sig-
nificance was considered when p < 0.05 with a 95% confidence interval. 
The concentration required to reduce cell viability/proliferation by 50% 
(IC50) or to induce cytotoxicity by 50% (EC50) was graphically deter-
mined using the curve fitting algorithm of GraphPad Software. For the in 
vivo experiments, equal numbers of animals were selected and randomly 
distributed into each treatment group. The minimal number of animals 
to be used was determined with statistical power and sample size 
analysis using G Power 3.1 Software (Düsseldorf, Germany) and fol-
lowed the OECD recommendation (N◦407). 
Table 1 
Gene names and primer sequences (5′- 3′) used for real-time qPCR.  
Gene Forward primer (5 ¡́3 )́ Reverse primer (5 ¡́3 )́ 
BCR GGA GTC ACT GCT GCT GCT TA ACA CTT CTT CTG CTG CTC CC 
b3a2 GAG CGT GCA GAG TGG AGG 
GAG AAC ATC CGG 
TGT GAT TAT AGC CTA AGA CCC 
GGA GCT TTT 
MYC CCAGCAGCGACTCTGAGG CCAAGACGTTGTGTGTTC 
PIM1 GCTCGGTCTACTCAGGCATC CATTAGGCAGCTCTCCCCAG 
SOCS2 CAG ATG TGC AAG GAT AAG CGG CAG ATA AAG GTG AAC AGT GCC 
G 
GAPDH CCATGGAGAAGGCTGGGG CAAAGTTGTCATGGATGACC  
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3. Results 
3.1. Antitumoral efficacy of JKST6 on human leukemia cells 
JKST6 was identified within a naphthoquinone-enriched library by 
high-throughput cell-based phenotypic screening (Fig. 1A). First, the 
antitumoral effects of JKST6 were evaluated by MTT assay. Interest-
ingly, JKST6 showed higher efficacy against cell lines derived from 
hematological malignancies (i.e., K562, MOLM-13, HL-60, HEL, MV 
4.11, JURKAT cell lines) than against breast cancer-derived cells (i.e., 
BT-549, MDA-MB-231, HS-578 T) or nonmalignant cells (i.e., RAW 
264.7, Vero, hMSCs, and PBMCs) (Table 2). The cytotoxicity of JKST6 on 
quiescent human PBMCs was 4-fold lower than that in K562 cells 
(Table 2). Remarkably, low concentrations (1 and 3 µM) of JKST6 
showed no significant effect on PBMC viability compared to K562, 
whereas doxorubicin, a chemotherapeutic agent used in a broad spec-
trum of tumor types, reduced PBMC and K562 viability with similar 
potency (Fig. 1B). The low toxicity displayed by JKST6 in vitro was also 
validated in vivo. JKST6 (10 mg/kg) was administered to mice in acute 
(5 days, data not shown) and subchronic (30 days) toxicity assays. The 
results confirmed that the clinical signs, blood cell populations or 
biochemical parameters of JKST6-treated animals were mostly unaf-
fected when compared with those of the vehicle-treated group (Sup-
plementary Figure 1, Supplementary Tables 1–2). 
As shown in Table 2, JKST6 exhibits potent antitumoral effects in 
K562 cells, a model of human CML. Thus, we further investigated the 
irreversible effects of a short exposure (3 h) of K562 cells to JKST6. IM 
and doxorubicin were also analyzed in this set of experiments. The data 
revealed that JKST6 (IC50 = 1.57 ± 0.28 µM) and doxorubicin (IC50 =
0.74 ± 0.12 µM) maintained their antitumoral potency after short 
exposure (3 h) of K562 to the drugs followed by 48 h of wash-out, 
whereas IM reduced its antitumoral effect (IC50 > 5 µM) (Fig. 1C). 
These results suggest that short and transient exposure to JKST6 is 
enough to maintain, at least for 48 h, the inhibitory effects induced by 
Fig. 1. Antitumoral efficacy of JKST6 on human leukemia cells. (A) Chemical structure of JKST6; the pyrone group is highlighted in color. (B) Cell viability 
measured in K562 and PBMC cells incubated with JKST6 or doxorubicin (DOXO) (both at 1 and 3 μM) for 24 h. (C) Cell viability measured in K562 cells exposed to 
graded concentrations (0.01–10 μM) of JKST6 ( ), DOXO ( ) or IM (○) for 3 h followed by wash-out steps. (D) Proliferation and cytotoxicity in K562 cells treated 
with vehicle (VEH; 0.05% DMSO) or JKST6 (0.01–10 μM) for 5 days. Data represent the area under the curve (AUC) by JKST6 dose (left panel) and representative 
microphotographs of exponentially growing K562 cells under VEH or JKST6 (3 μM) conditions at 0, 24, 48, 72 and 120 h (right panel). (E) 3D cultures of K562 cells 
exposed to VEH, JKST6 (2, 3, and 5 µM), or IM (0.5 and 1 µM) for 5 days. Representative microphotographs of tumor spheroids in the absence (VEH) or presence of 
compounds (3 µM JKST6 and 0.5 µM IM) at 24, 48 and 72 h (right panel) and quantification of tumor volume calculated as a percentage of the control (left panel). 
(F) Representative green fluorescence microphotographs of YOYO-1-labeled K562 tumor spheroids in the absence (VEH) or presence of compounds (3 µM JKST6 and 
0.5 µM IM) at 24, 48 and 72 h. Figures are representative of at least 3 independent experiments, each performed in triplicate. Statistical significance was assessed 
using one-way ANOVA with Bonferroni post hoc test. *P < 0.05; ** P < 0.01; ***P < 0.001; ****P < 0.0001 versus VEH-treated cells. 
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this new product on K562 cell viability. 
Furthermore, 2D real-time monitoring of K562 cell growth permitted 
to discern cytostatic (lower than 1 µM) and cytotoxic (higher than 3 µM) 
JKST6 doses in a long-term experiment (5 days) (Fig. 1D). Instead, IM 
showed a cytostatic effect around 0.25 µM and cytotoxic effects at doses 
higher than 1 µM (data not shown). As a representative image, bright-
field microphotographs of K562 cells exposed to 3 µM JKST6 or vehicle 
are shown (Fig. 1D). In addition, kinetic studies showed the rapid 
antiproliferative effects of JKST6 (IC50 = 0.91 µM at 12 h) compared to 
IM (IC50 > 5 µM at 12 h) (Supplementary Figure 2). To better mimic a 
real tumor in vivo, 3D spheroid experiments with K562 cells were per-
formed. Notably, JKST6 significantly reduced spheroid growth 
compared to vehicle-treated K562 cells (Fig. 1E). Moreover, JKST6 
cytotoxicity especially affected the K562 spheroid perimeter at short 
times (48 h) when compared to IM cytotoxicity (Fig. 1F). Taken 
together, these results show that JKST6 has a rapid and long-term 
antitumor effect in CML cells and that its low toxicity in healthy cells 
might be clinically relevant. 
3.2. JKST6 inhibits cell cycle entry and induces apoptosis in human CML 
cells 
To further evaluate the manner in which JKST6 suppresses K562 cell 
growth, we performed cell cycle profiles and apoptosis studies by flow 
cytometry. As shown in Fig. 2A-B, all doses of JKST6 promoted a sig-
nificant increase in the subG1 phase, accompanied by a corresponding 
decrease in the G0/G1 phase, especially after 24 and 48 h of drug 
exposure. Consistently, changes in proteins involved in cell cycle regu-
lation were also observed after JKST6 treatment (Fig. 2C). In particular, 
the compound markedly reduced the phosphorylation of pRB, a protein 
that controls cell cycle entry, at only 6 h posttreatment, whereas Cyclin 
E, which is associated with G1-S transition, showed a peak at 24 h fol-
lowed by a reduction at 48 h. Proteins that have key roles in the S and M 
phases were also altered by JKST6. Thus, JKST6 increased Cyclin A and 
B levels after 48 h of treatment. We also observed that Wee1, a check-
point protein that negatively controls mitosis entry, was phosphorylated 
at short times of compound exposure. A reduction in the activation of 
H3, a histone that is phosphorylated in different patterns in mitosis, was 
also evident from 6 to 48 h posttreatment. Moreover, certain negative 
regulators of mitosis progression (pCHK1, pCHK2, p21) were activated 
after JKST6 treatment (Fig. 2C). 
The increase in subG1 phase implies an enhanced number of 
hypodiploid cells, which in turn represent dead cells. To identify the 
mechanism of death induced by JKST6, we performed apoptosis assays 
that measured Annexin V and propidium iodide (PI) staining using doses 
and time points used for cell cycle analysis. Significant time- and dose- 
dependent increases in Annexin V-positive cells were detected 
(Fig. 3A), along with an increase in the number of apoptotic nuclei 24 h 
after JKST6 treatment (Fig. 3B). Apoptotic death can be dependent or 
independent of the activity of certain caspases. Therefore, to better 
understand the death mechanisms activated by JKST6, different initiator 
and effector procaspases, as well as poly (ADP-ribose) polymerase 
(PARP), were studied. As shown in Fig. 3C-D, JKST6 treatment induced 
the cleavage and activity of procaspases 8 and 9 at 12 h, whereas the 
cleavage of procaspase-3 and PARP was detected from 12 to 48 h after 
treatment. Moreover, phosphorylation of the DNA double strand breaks 
marker H2AX was detected just 6 h after treatment, which, together 
with Chk1 and Chk2 activation, indicated the presence of genetic 
damage. Finally, Mcl-1, a pro-survival Bcl2 family protein, was induced 
after short-term JKST6 treatment (Fig. 3C). Taken together, these data 
revealed that JKST6 reduces K562 cell growth, inhibits cell cycle entry, 
causes DNA damage, and induces apoptosis. 
3.3. JKST6 inhibits BCR-ABL1/STAT5 and modulates associated 
survival pathways in human chronic myelogenous leukemia 
To determine whether JKST6 effectively targets the BCR-ABL1/ 
STAT5 signaling pathway, protein and mRNA expression analyses 
were performed in K562 cells. Interestingly, hyperphosphorylation of 
BCR-ABL1 (pY412 and pY177) was efficiently inhibited by JKST6 (3 µM at 
3 h) (Fig. 4A). However, this finding was concomitant with a reduction 
in the chimeric BCR-ABL1 protein measured in ABL and BCR domains, 
whereas BCR and c-ABL wild-type proteins remained practically unal-
tered after JKST6 treatment (Fig. 4A). Importantly, constitutive phos-
phorylation of pSTAT5Y694 was inhibited after JKST6 treatment without 
altering total STAT5 levels (Fig. 4A). To explore the mechanism that 
causes a reduction in BCR-ABL1 after JKST6 treatment, the levels of 
polyubiquitinated proteins were studied. The results showed evident 
increases in ubiquitinated proteins after short-term treatments (0.5, 1 
and 3 h) compared to vehicle-treated cells (Fig. 4A). The extent of the 
posttranslational effect caused by JKST6 was studied using a proteasome 
inhibitor (MG132) to block proteolytic activity [34] prior to compound 
addition, as shown in Fig. 4B. Cells were pretreated with MG132 for 2 h 
before JKST6 treatment for another 1, 3 or 6 h. First, JKST6 alone caused 
a peak in ubiquitinated proteins at 1 h after treatment, as previously 
observed. MG132 induced an evident increase in ubiquitinated proteins 
compared with the vehicle at all time points. Moreover, MG132 (2 h) 
followed by JKST6 resulted in the potentiation of ubiquitinated proteins 
after 1 and 3 h of treatment and, importantly, partially prevented the 
JKST6-induced downregulation of BCR-ABL1 protein at 1 h. Surpris-
ingly, the mixture enhanced the reduction in total oncoprotein levels 
after 3 and 6 h of treatment (Fig. 4B). 
The expression of other key components involved in BCR-ABL1/ 
STAT5 signaling was analyzed, including CrkL [35], c-MYC and PIM1 
[4]. As shown in Fig. 4C, all these proteins were also downregulated by 
JKST6 treatment, thus indicating a blockage of the BCR-ABL1/STAT5 
downstream cascade by the compound. To understand whether STAT 
transcription factor activity may be downregulated by JKST6, Renilla 
luciferase assays were performed. Notably, in the BaF3 reporter cell line, 
JKST6 inhibited IL3-induced STAT5 luciferase activity 
(IC50 = 4.26 ± 0.05 µM) without disturbing cell viability (IC50 =
9.58 ± 0.58 µM) (Fig. 5A). Although less potent 
(IC50 = 7.18 ± 1.48 µM), JKST6 treatment also decreased IL6-induced 
STAT3 transcriptional activity in the HEK293 reporter cell line without 
causing toxicity (IC50 > 10 µM) (Fig. 5B). RNA analysis was performed 
to assess whether JKST6 provokes gene expression inhibition alongside 
protein content reduction of BCR-ABL1 using two different primer pairs 
that amplify exons 12 and 13 of BCR (BCR) and the junction region of 
Table 2 
Effects of JKST6 on cancer (blood and solid tumors) and normal cell 
viability.  
Cell line IC50 (µM; mean ± SEM) 
K562  0.66 ± 0.29 
MOLM-13  0.71 ± 0.20 
HL-60  0.88 ± 0.09 
HEL  1.02 ± 0.16 
MV4.11  1.04 ± 0.08 
ISHIKAWA  1.43 ± 0.19 
JURKAT  1.69 ± 0.01 
BT-549  1.99 ± 0.87 
MCF10A  2.27 ± 0.16 
MDA-MB-231  2.70 ± 0.16 
MCF7  3.18 ± 0.21 
HS-578T  3.25 ± 1.20 
hMSC-TERT  4.61 ± 1.27 
SKBR3  4.68 ± 0.62 
RAW 264.7  5.13 ± 0.95 
PMBC  5.68 ± 0.9 
VERO  6.44 ± 2.02 
EVB lymphocytes  > 10 ± ND 
Cells were treated with vehicle (0.05% DMSO) or JKST6 
(0.01–10 µM) for 24–72 h. Then, cell viability was assessed by MTT 
assay as described in Material and Methods. ND: not determined. 
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Fig. 2. JKST6 blocks cell cycle entry in human 
chronic myelogenous leukemia cells. (A) Cell 
cycle studies in K562 cultures treated with vehicle 
(VEH; 0.05% DMSO) or different doses of JKST6 
(1, 1.5 and 2 µM) for 12, 24 and 48 h. Represen-
tative FACS images classifying cells according to 
their profiles in subG1, G0/G1, S, and G2/M 
phases. (B) Quantification of the percentages of 
cells in the different subregions at each time point 
shown in Panel A. Figures are representative of 
three independent experiments, each performed 
in triplicate. (C) Cell cycle protein expression 
analysis by immunoblotting assay from total cell 
lysates of K562 cells exposed to JKST6 (2 μM) for 
6, 12, 24 and 48 h. Calnexin was used as a loading 
control. Figures are representative of two inde-
pendent experiments. Statistical significance was 
assessed using one-way ANOVA with Bonferroni 
post hoc test. *P < 0.05; **P < 0.01versus VEH- 
treated cells.   
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the oncoprotein (b3a2). In addition, STAT5 target genes (MYC and 
PIM1) were also studied (Fig. 5C). Notably, the relative gene expression 
profile showed a different pattern of suppression than the one detected 
in the immunoblot assays, highlighting the earlier decrease in BCR-ABL1 
protein levels (3 h posttreatment) followed by later reductions in BCR 
and b3a2 mRNA levels (12 h posttreatment). Sustained MYC mRNA 
downregulation was produced by JKST6, whereas PIM1 downregulation 
was observed at short times followed by enhanced expression at 12 h. 
Finally, alternative survival pathways also modulated by BCR-ABL1 
in CML were analyzed [7]. Accordingly, JKST6 inhibited the phos-
phorylation of Src family kinases at 12 h, as well as P38-MAPK and S6, 
and transiently augmented AKT and JNK phosphorylation when 
compared to nontreated K562 cells (Fig. 6A-B). ERK1/2 phosphoryla-
tion seemed to be increased at 30 min and remained augmented until 
12 h after treatment (Fig. 6A). Therefore, these results suggest that 
JKST6 negatively modulates the BCR-ABL1/STAT5 pathway in K562 
cells. 
3.4. JKST6 potentiates imatinib-induced antiproliferative effects and 
STAT5 inhibitory activity 
Drug combinations allow the use of lower doses that hinder drug 
resistance development or promote more effective target inhibition 
[21]. Hence, to evaluate whether JKST6 enhances the antiproliferative 
effect of IM, dose–response synergistic assays combining both com-
pounds were performed. For these studies, IM-sensitive 
K562-GFP+ cells were treated with different doses of JKST6 and IM, 
following a constant ratio combination design [7.5(JKST6):1(IM)] at 
different time points. Very interestingly, we found a significant increase 
in IM potency compared with IM alone when combined with JKST6 at all 
time points (Fig. 7A). Furthermore, isobologram and Chou-Talalay an-
alyses of the combination index (CI) [32] showed that JKST6 and IM 
acted synergistically in inducing antiproliferative effects (CI (24 h) for 
ED50 = 0.42 ± 0.10 and CI (24 h) for ED75 = 0.38 ± 0.11)/(CI (48 h) 
for ED50 = 0.55 ± 0.16 and CI (48 h) for ED75 = 0.46 ± 0.13) 
(Fig. 7B). Importantly, synergistic effects of the JKST6-IM combination 
on pSTAT5Y694 levels were also observed. Thus, when K562 cells were 
treated with different combination doses of IM (0.03 or 0.05 µM) and 
JKST6 (0.5 or 1 µM) for 3 h, the phosphorylation of STAT5 at Y694 was 
significantly more inhibited than when cells were treated with individ-
ual compounds (Fig. 7C). 
3.5. JKST6 reduces cell growth, cell viability and the BCR-ABL1/STAT5 
signaling pathway in imatinib-resistant cells 
Resistance to IM treatment has been associated, among other 
mechanisms, with the T315I-BCR-ABL1 mutation, BCR-ABL1 over-
expression or antidrug transporters [12]. For this reason, the capacity of 
JKST6 to extend its antitumoral effect to IM-resistant cells was studied in 
a series of viability assays, as indicated in Table 3. First, IM-resistant and 
IM-sensitive K562 cells (K562-R and K562, respectively) were treated 
with increasing concentrations of IM or JKST6 for 48 h. As we previ-
ously described [22], the IM-IC50 was approximately 20 times higher in 
K562-R cells (3.86 ± 0.37 µM) than in K562 cells (0.14 ± 0.05 µM), 
whereas JKST6 displayed similar antitumoral efficacy in both cell line 
models (IC50 = 1.03 ± 0.11 µM and IC50 = 0.66 ± 0.09 µM in K562-R 
Fig. 3. JKST6 induces apoptosis in K562 cells. (A) Analysis of apoptosis in K562 cells treated with vehicle (VEH; 0.05% DMSO) or JKST6 (1, 1.5 and 2 µM) for 12 
and 24 h using the Annexin V-FITC apoptosis detection kit. Representative FACS images of the measurement of phosphatidylserine translocation to the cell surface 
(upper panel) and quantification of the percentages of Annexin V (-) and Annexin V (+) cells at each time point (lower panel). Graphs are representative of three 
independent experiments, each performed in triplicate. (B) Fluorescence microscopy microphotographs of K562 cells stained with bisbenzimide to identify apoptotic 
nuclei after JKST6 (1 µM and 2 µM) treatment for 24 h. Arrows mark apoptotic cells with condensed chromatin (upper panel), with percentage representation of 
apoptotic nuclei (lower panel). (C) Immunoblotting analysis of proteins involved in apoptosis from total cell lysates of K562 cells exposed to VEH or JKST6 (2 µM) 
for 6, 12, 24 and 48 h. Calnexin was used as a loading control. Representative images from two independent experiments are shown. (D) Analyses of caspase-8, − 9, 
and − 3 activities determined in K562 cells exposed to VEH, JKST6 (2 µM) or etoposide (ETP) (30 µM) for 6, 12 and 24 h. The results represent the fold increase in 
caspase activity compared to VEH. Figures are representative of two independent experiments, each performed in duplicate. Statistical significance was assessed 
using one-way ANOVA with the Bonferroni post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 versus VEH-treated cells. 
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and K562 cells, respectively) (Fig. 8A). Remarkably, a low JKST6-IC50 
value was obtained in a K562-transfected clone expressing the 
T315I-BCR-ABL1 mutation [27], recognized as a key mechanism of IM 
resistance (Table 3). However, IM treatment was clearly ineffective in 
these cells (Table 3). Additionally, the AR230 cell line is a CML model 
with IM-sensitive (AR230) and IM-resistant (AR230-R) clones which 
carry a 230-kDa BCR-ABL1 fusion variant and exhibits IM resistance 
through oncoprotein overexpression [36], showing 12 times lower 
responsiveness to IM (AR230-R) than its IM-sensitive counterpart, 
AR230 (1.89 ± 0.55 µM and 0.15 ± 0.02 µM, respectively). In contrast, 
the IC50 values obtained for JKST6 were similar in both cell clones 
(1.52 ± 0.31 µM and 1.57 ± 0.49 µM in AR230-R and AR230 cells, 
respectively) (Table 3). 
To examine the irreversible effects of JKST6 on IM-resistant cells, 
wash-out experiments were performed by short-term exposure (3 h) of 
K562-R cells to JKST6, doxorubicin or IM followed by drug removal 
from the media for 48 h. As expected, IM was ineffective (IC50 >5 µM), 
whereas both JKST6 (IC50 = 2.86 ± 0.17 µM) and doxorubicin (IC50 =
2.12 ± 1.12 µM) were able to significantly reduce the viability of K562- 
R cells (Fig. 8B). Predictably, live cell imaging of K562-R proliferation in 
long-term experiments (5 days) showed that IM was less potent on K562- 
R cells (IC50 = 4.55 ± 1.31 µM) than on K562 cells (IC50 =
0.24 ± 0.2 µM), whereas JKST6 remained equally effective in both cases 
(IC50 = 1.07 ± 0.19 µM versus IC50 = 0.75 ± 0.10 µM) (Fig. 8C). For a 
pathophysiological approach, 3D spheroid live-cell imaging assays were 
performed in AR230-R cells and showed a JKST6 dose-time-dependent 
volume shrinkage, whereas IM was unable to exert a significant effect 
on tumor volume (Fig. 8D). Moreover, JKST6 caused rapid (24 h) 
damage to peripheral cells, while IM cytotoxicity was visible at 24 and 
48 h but seemed to be ineffective at 72 h (Supplementary Figure 3A). 
Finally, due to the importance that BCR-ABL1 overexpression has in IM 
resistance, we investigated whether JKST6 maintained its molecular 
mechanism of action in AR230-R cells using AR230 cells as a control 
(Fig. 9A). Notably, 3 µM JKST6 effectively reduced the levels of total 
BCR-ABL1 in both clones and thus BCR-ABL1 phosphorylation (pY177, 
pY412) at just 3 h after treatment (Fig. 9A). Likewise, hyper-
phosphorylation of STAT5 (higher in AR230-R cells) and PIM1 and c- 
MYC protein expression levels were significantly inhibited at 3 h of 
JKST6 exposure. In contrast, IM was considerably less efficient in 
inhibiting BCR-ABL1 and STAT5 phosphorylation in IM-resistant 
AR230-R cells (Fig. 9A-right panel) than in their IM-sensitive coun-
terparts (Fig. 9A-left panel). Moreover, JKST6 induced γH2AX (at 3, 6 
and 12 h after treatment) and reduced CrkL phosphorylation (at 6 and 
12 h after treatment) to a similar extent in both cell clones. However, IM 
was not able to induce γH2AX phosphorylation in AR230-R cells 
(Fig. 9A-right panel). To investigate whether the reduction in BCR- 
ABL1 protein levels by JKST6 could contribute to restoring the 
(caption on next column) 
Fig. 4. JKST6 suppresses the BCR-ABL1/STAT5 signaling pathway and 
modulates posttranslational mechanisms associated with protein degra-
dation. (A) Immunoblotting detection of phosphorylated (pY412)/(pY177) and 
total levels of BCR-ABL, BCR, c-ABL, STAT5 and polyubiquitin from whole-cell 
extracts of K562 cultures previously treated with vehicle (VEH; 0.05% DMSO), 
JKST6 (3 μM) or IM (1 µM) for the indicated times. (B) Immunoblotting 
detection of phosphorylated (pY412) and total levels of BCR-ABL1 and c-ABL 
and polyubiquitin from total cell lysates of K562 cells pre-exposed to the pro-
teasome inhibitor MG132 or VEH for 2 h followed by VEH or JKST6 (3 μM) 
treatment for the indicated times. (C) Immunoblotting analysis of BCR-ABL1/ 
STAT5 axis-downstream proteins (pY207-CrkL, CrkL, PIM1, c-MYC) from cell 
lysates of K562 cells treated with VEH, JKST6 or IM for the indicated times. 
β-actin was used as a loading control. Representative images from three inde-
pendent experiments are shown. 
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Fig. 5. JKST6 inhibits STAT5- and STAT3- 
dependent transcription and BCR-ABL1 onco-
gene and STAT5-target gene expression. (A) 
STAT5 transcriptional activity measured by lucif-
erase assay in the BaF3 reporter cell line exposed to 
vehicle (VEH; 0.05% DMSO) or increasing concen-
trations of JKST6 (0.3–10 μM) for 4 h followed by 
STAT5 transcriptional activity induction (interleukin 
mIL3 (30 ng/ml), ) for 16 h in contrast with basal 
signal (not induction, ) (left panel). Cell viability 
measured in BaF3 cells analyzing the same JKST6 
doses and time points as in the luciferase assay (right 
panel). (B) STAT3 transcriptional activity measured 
in the Renilla luciferase HEK293 reporter cell line 
exposed to VEH or increasing concentrations of 
JKST6 (0.3–10 μM) for 4 h followed by STAT3 tran-
scriptional activity induction (interleukin hIL6 
(10 ng/ml), ) compared with basal signal (not in-
duction, ) (left panel). Cell viability measured in 
HEK293 cells analyzing the same JKST6 doses and 
time points as in the luciferase assay (right panel). 
Luciferase activity was measured as explained in the 
Materials and Methods. The maximal effect of lucif-
erase activity (100%) was assigned to VEH-treated 
cells stimulated with (mIL3 or hIL6) interleukin, 
and the rest of the dose effects were normalized by 
this value. Figures are representative of at least two 
independent experiments, each performed in dupli-
cate. Statistical significance was assessed using one- 
way ANOVA with Bonferroni post hoc test. 
*P < 0.05; **P < 0.01; ****P < 0.0001 versus VEH- 
treated and mIL3 (A) or hIL6 (B)-stimulated cells. 
(C) mRNA expression analysis by qPCR of BCR- 
ABL1/STAT5 axis-target oncogenes (BCR; b3a2; 
PIM1, c-MYC and the housekeeper GAPDH) in K562 
cells treated with VEH ( ), JKST6 (3 µM, ) or IM 
(1 µM, ) for the indicated times. Data are presented 
as the mean ± SEM of three independent experi-
ments, each performed in duplicate. Statistical sig-
nificance was assessed using one-way ANOVA with 
Bonferroni post hoc test. *P < 0.05; **P < 0.01; 
**** P < 0.0001 versus VEH-treated cells.   
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sensitivity of AR230-R cells to IM, cells were pre-exposed to vehicle or 
JKST6 for 3 h, followed by wash-out, and the dose effect on IM was 
evaluated at 48 h (Fig. 9B). Of interest, IM potentiated its effects by 14 
times when cells were pretreated with JKST6 (IC50 =
0.175 ± 0.003 µM) compared to vehicle pre-exposed cells (IC50 =
2.17 ± 0.17 µM). JKST6 inhibited the same key proteins involved in the 
BCR-ABL1/STAT5 pathway in the AR230 and K562 CML models; thus, 
the effect of JKST6 on mRNA expression was analyzed in K562-R cells 
(Fig. 9C). JKST6 provoked a different modulatory pattern of mRNA 
expression when compared to the protein levels, according to previous 
studies in K562 cells. The gene expression of SOCS2, a negative regulator 
of the JAK/STAT pathway associated with CML progression to the 
aggressive blast phase [37], was also assessed in both K562 and K562-R 
cells (Fig. 9C). IM treatment reduced the expression of SOCS2, whereas 
JKST6 provoked a peak of induction at 6 h in both cell lines. In sum-
mary, JKST6 displays the same potential for inhibiting the 
BCR-ABL1/STAT5 signaling pathway and its downstream effectors in 
both IM-resistant and IM-sensitive cells. Importantly, JKST6 might 
rescue the sensitivity of IM-resistant CML cells to IM. 
4. Discussion 
NPQ derivatives have emerged as promising therapeutic agents in 
cancer in the last decade. The present work reveals the pharmacological 
efficacy of a novel NPQ-pyrone hybrid, JKST6, in human CML cells and 
shows the molecular mechanisms responsible for its potent antitumoral 
effects. Interestingly, we show how the JKST6 compound is effective in 
overcoming imatinib resistance in a wide range of resistant cells with 
known resistance mechanisms present in CML patients; thus, it is a 
promising new pharmacological tool that could improve current thera-
peutic opportunities. 
Antiproliferative capacity and low toxicity are two crucial aspects of 
a clinically relevant antitumoral drug. Therefore, the antiproliferative 
effects of JKST6 in hematological and nonhematological cancer and 
normal cells were investigated. Our data show that JKST6 effectively 
inhibits the growth of human leukemia cells with high potency (i.e., sub 
µM IC50 values in K562 and MOLM-13) compared to solid tumor cells (e. 
g., BT-549, MDA-MB-231, MCF7). Remarkably, the viability of nonma-
lignant cells was hardly affected by JKST6 treatment, which agrees with 
the low toxicity observed by compound administration in vivo. These 
results suggest that JKST6 may find specific molecular targets in 
myeloid-derived cancer cells, which makes them more sensitive to the 
compound than other leukemias or nonhematological cancer cells. 
JKST6 displays rapid antiproliferative activity and longer-lasting anti-
tumoral effects on CML cells after short drug exposure when compared 
to the BCR-ABL1 inhibitor IM. These findings outline a JKST6 durable 
action that is normally associated with ligand-target covalent bonds, 
long drug-target residence, or posttranslational effects after drug-target 
union [38,39]. Interestingly, JKST6 shows a wide window between 
cytostatic and cytotoxic doses, coinciding with reported studies of 
pyrones that display elevated antiproliferative over cytotoxic activity 
[40]. Moreover, the antitumor efficacy of JKST6 was validated in CML 
cell spheroids, a culture system that faithfully reproduces tumor biology 
in vivo. In fact, differences between 2D monolayer and 3D cultures have 
been widely reported, and some of them include signal transduction, 
gene and protein expression, cell differentiation or drug sensitivity [41]. 
Furthermore, recent studies have found that leukemic cells are meta-
bolically more stable in 3D than in 2D standard cultures, where they are 
prone to undergo phenotypic changes with passage [42]. Thus, the 
growth inhibition of CML spheroids induced by JKST6 in vitro may 
represent a valid approach for its potential antitumor efficacy in vivo 
[41]. 
It has been reported that NPQ-based derivatives and hybrids are able 
to induce antiproliferative effects on CML cells through diverse mech-
anisms, including oxidative stress, cell cycle arrest, apoptosis, inhibition 
of BCR-ABL1/STAT5 signaling and modulation of other survival path-
ways [21,22,43]. Accordingly, we have previously shown that 
quinone-containing compounds inhibit CML cell growth through cell 
cycle arrest [21,22]. Examples include the NPQ-based derivative 
CM363, which induces cell cycle arrest through augmented S phase 
[21], and the NPQ-coumarin hybrid NPQ-C6, which increases subG1 
and reduces G0/G1 cell cycle phases [22]. In the present study, we 
demonstrate that JKST6 alters the CML cell cycle by augmenting subG1 
and reducing G0/G1 phases in a time- and dose-dependent manner with 
higher potency than its precursor NPQ-C6 [22]. Importantly, these ef-
fects are associated with changes in the phosphorylation and/or 
expression of several proteins involved in cell cycle progression. Thus, 
JKST6 reduced retinoblastoma (RB) phosphorylation, which is neces-
sary for cell cycle progression and is normally associated with cyclin 
Fig. 6. JKST6 modulates important alternative survival pathways in CML. 
Protein expression analysis by immunoblotting assay of phosphorylated and 
total key signaling proteins (A) (pY416-Src, Src, pT183/Y185-JNK, JNK1/3, 
pT202/Y204-ERK1/2; ERK1/2; pT180/Y182-p38-MAPK, p38-MAPK; (B) pT308- 
AKT, AKT, pS473-AKT, AKT, pS240/244-S6, S6) from whole-cell extracts of K562 
cells exposed to vehicle (VEH; 0.05% DMSO), JKST6 (3 µM) or IM (1 µM) for 
the indicated times. β-actin was used as a loading control. Images are repre-
sentative of at least two independent experiments. 
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D/Cdk4 inhibition [44]. Downregulation of RB phosphorylation has also 
been related to c-ABL kinase inhibition, which in turn plays a role in S 
phase progression [45]. Moreover, complexes formed by cyclin E-CDK2, 
cyclin A-CDK2 and cyclin B-CDK1 regulate the G1/S transition, S phase 
progression, and G2/M transition, respectively [46]. Interestingly, 
JKST6 modulates these cyclins together with a significant increase in 
pCDK1Y15. This phosphorylation leads to CDK1 inactivation, which is 
controlled by the Wee1 and Cdc25 balance [46]. NPQ-containing com-
pounds have been previously identified as Cdc25 inhibitors [21,47], 
which block phosphatase activity and therefore CDK1 activation. 
Moreover, the phosphorylation of Wee1 at S642 has been reported to be 
AKT-dependent and to cause Wee1 inactivation [48]. In fact, JKST6 
transiently induces pWee1S642, which coincides with CDK1 active/-
inactive states. Similarly, JKST6 reduces mitotic histone 3 (H3) phos-
phorylation at Ser-10 (pH 3S10), which has been reported to be required 
for proper execution of mitosis [49]. Furthermore, JKST6 induces the 
expression of p21 protein, a negative regulator of G1 and G2 progres-
sion, which has been related to the antiproliferative effects of other 
NPQs (e.g., shikonin and plumbagin) on leukemic cells [43,50]. In 
addition, JKST6 strongly stimulates phosphorylation of the downstream 
effectors of the ATM/ATR-dependent DNA damage checkpoint 
(pChk1S296 and pChk2T68) at short times after compound exposure, 
suggesting an early and potent induction of genotoxicity by the com-
pound [51], which is a reported feature of NPQs and pyrones [52]. All 
these findings support the hypothesis that JKST6 prevents cell cycle 
progression by inducing cell arrest in the subG1 phase and triggering 
mitosis alterations, effects that might be caused, at least in part, by DNA 
damage. 
Loss of apoptotic control allows cancer cells to survive longer; 
therefore, regulation of apoptosis constitutes a hotspot for any antitu-
moral drug. In this sense, JKST6 induces apoptosis in K562 cells, as 
assessed by increased Annexin V activity, apoptotic nuclei, activation of 
caspase-8, − 9 and − 3 and PARP cleavage. Previous studies have shown 
that NPQ derivatives and hybrids are able to induce apoptosis in CML 
cells through the induction of the intrinsic mitochondrial-dependent 
pathway [21,22,43], which involves the activation of caspases 9 and 
3. However, the activation of caspase-8 (apoptosis extrinsic pathway) 
has also been implicated in NPQ-induced apoptosis in human leukemia 
cells [53]. Paradoxically, JKST6 upregulates the antiapoptotic protein 
Mcl-1, an effect that has also been reported in myeloid leukemia cells in 
response to certain chemotherapeutics [54]. Notably, JKST6 promotes 
an early increase in the double-strand DNA break marker γH2AX, further 
reinforcing the hypothesis that the compound triggers DNA damage 
related to the apoptotic process that cannot be repaired by CML cells. 
Cell cycle arrest and activation of apoptosis induced by NPQ-based 
derivatives and hybrids in CML cells are generally associated with 
potent downregulation of BCR-ABL1/STAT5 signaling [21,22]. 
Accordingly, JKST6 leads to a rapid decrease in BCR-ABL1 phosphory-
lation (pY412 and pY177) in CML cells, which can be explained by a 
concomitant reduction in its total protein levels. These fast responses are 
Fig. 7. JKST6 and imatinib coadministration acts synergistically in cell proliferation and STAT5 phosphorylation inhibition. (A) Representative image of 
cell proliferation measured in K562-GFP+ cells exposed to a constant ratio combination of different concentrations of JKST6 and imatinib (IM) (Mixture). Data are 
presented as the percentage of green confluence by IM concentration at 24 h (upper panel) and 48 h (lower panel). (B) Proliferation data analyzed by isobologram 
in K562-GFP+ cells treated with JKST6 (8 doses; from 0 to 5 μM), IM (8 doses; from 0 to 1 μM) or both in combination (constant ratio design (7.5 (JKST6):1 (IM)) for 
24 and 48 h. The effect varied from 0 (no cell proliferation inhibition) to 1 (100% cell proliferation inhibition) using Calcusyn® software, as described in the 
Materials and Methods. Data are representative of four independent experiments with four replicates each. CI values (mean ± SEM) for ED25, ED50, ED75 and ED90 
are symbolized as $ (antagonism), & (additive) or * (synergism). (C) Immunoblotting analysis of phosphorylated and total levels of STAT5 in whole cell lysates from 
K562 cultures treated with vehicle (0.05% DMSO), JKST6 (0.5 or 1 μM), IM (0.03 or 0.05 μM) or both drugs for 3 h. β-actin was used as a loading control. Images are 
representative of at least two independent experiments. 
Table 3 
Effects of JKST6 and IM on IM-sensitive or -resistant chronic myelogenous leu-
kemia (CML) cells.  
Cell line JKST6- IC50 values (µM; mean 
±SEM) 
IM- IC50 values (µM; mean 
±SEM) 
K562  0.66 ± 0.29  0.14 ± 0.05 
K562-R  1.03 ± 0.13  3.86 ± 0.37 
AR230  1.52 ± 0.31  0.15 ± 0.02 
AR230-R  1.57 ± 0.49  1.89 ± 0.55 
KmycBT315I  1.79 ± 0.25  15.13 ± 1.72 
Cells were treated with vehicle (0.05% DMSO), JKST6 (0.01–10 µM) or IM 
(0.03–20 µM) for 48 h. Then, cell viability was assessed by MTT assays as 
described in Material and Methods. 
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Fig. 8. JKST6 reduces cell viability and 
growth and downregulates the BCR-ABL1/ 
STAT5 signaling pathway in imatinib (IM)- 
resistant cells. (A) Cell viability measured in 
IM-sensitive (K562) cells ( , ) and IM- 
resistant (K562-R) cells ( , ) incubated with 
vehicle (0.05% DMSO) or different concentra-
tions of JKST6 ( , ) or IM ( , ) for 48 h. (B) 
Cell viability measured in K562-R cultures 
exposed to vehicle or graded concentrations 
(0.01–10 μM) of JKST6 ( ), DOXO ( ) or IM 
( ) for 3 h, followed by wash-out steps as 
explained in the Materials and Methods. (C) 
Proliferation ( ) and cytotoxicity ( ) measured 
with the IncuCyte™ HD real-time analysis sys-
tem in K562-R cells treated with vehicle, JKST6 
(0.01–10 μM) or IM (0.01–5 μM) for 5 days. 
Data are plotted as the area under the curve 
(AUC) by JKST6 dose (left panel). Represen-
tative microphotographs of proliferating K562- 
R cells in the absence (vehicle (0.05% DMSO): 
VEH) or presence of JKST6 (3 μM) or IM (3 μM) 
for 24, 48 and 72 h (right panel). (D) 3D cul-
tures of IM-sensitive AR230 and IM-resistant 
AR230-R cells treated with JKST6 (2, 3 and 
5 µM), IM (0.5 and 1 µM) or VEH for 5 days. 
Spheroid growth and cytotoxicity were moni-
tored using the IncuCyte real-time system, and 
tumor volume was calculated as the percentage 
of the control in AR230-R (upper left panel) 
and AR230 cells (lower left panel). Illustrative 
microphotographs of AR230-R tumor spheroids 
in the absence (VEH) or presence of compounds 
JKST6 (3 and 5 µM) or IM (0.5 µM) for 24, 48 or 
72 h (right panel). Figures are representative of 
at least two independent experiments, each 
performed in triplicate. Statistical significance 
was assessed using one-way ANOVA with Bon-
ferroni post hoc test. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001 versus VEH- 
treated cells.   
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often associated with posttranslational events, predominantly regulated 
by ubiquitin conjugation and proteasome activation [55]. In fact, a rapid 
decrease in BCR-ABL1 protein levels has been described for drugs that 
alter the ubiquitin cycle [14,56]. Accordingly, JKST6-induced down-
regulation of BCR-ABL1 protein was preceded by an increased level of 
polyubiquitinated proteins. Importantly, previous inhibition of the 
proteasome by MG132 [34] followed by JKST6 treatment partially 
prevented JKST6-induced BCR-ABL1 protein downregulation at 1 h 
after treatment and provoked an increased level of polyubiquitinated 
proteins. These findings suggest that proteasome activation might 
contribute, at least in part, to the effects of JKST6 on CML. Moreover, 
protein polyubiquitination and decay were followed by a reduction in 
BCR-ABL1 mRNA levels, which supports the hypothesis that protein 
degradation precedes the inhibition of gene transcription. Although the 
exact posttranslational mechanism implicated in these effects deserves 
future research, compounds that cause ubiquitin cycle disturbances have 
been described as a successful approach to reduce BCR-ABL1 levels and 
subsequently activate cell death even in IM-resistant CML cells [14]. 
Interestingly, the rapid inhibition of BCR-ABL1 is effective down-
stream. In particular, the JKST6-induced inhibition of pSTAT5Y694 pre-
dictably plays a key role in the antiproliferative effects of this compound 
due to its crucial roles in cell transformation, survival and growth in this 
neoplasm [4]. JKST6 also shows important functional effects inferred 
from the inhibition of pCrkLY207 and STAT5 target genes, such as PIM1 
and c-MYC. These findings are particularly relevant, as c-MYC and 
BCR-ABL1 can upregulate each other; MYC participates in cell trans-
formation, genomic instability and suppression of cell differentiation, 
thus favoring a poor response to IM and therefore a higher aggressive-
ness of disease [22,27]. Moreover, c-MYC inhibition caused by 
NPQ-based derivatives and hybrids has directly been linked with 
apoptosis induction in CML [21,22,57]. PIM1 is also upregulated by 
BCR-ABL1/STAT5 signaling and has roles in cell survival, 
transformation, and apoptosis protection against DNA damage [58]. 
Furthermore, PIM1 inhibition has been seen to play a central role in the 
anti-CML pharmacological actions of NPQ-based derivatives and hybrids 
[21,22]. Interestingly, we observed that JKST6 also had a regulatory 
role in STAT-mediated transcriptional activity, evidenced by the inhi-
bition of IL3/JAK2/STAT5-dependent transcription. Taken together, 
these results support the hypothesis that JKST6 downregulates the 
BCR-ABL1/STAT5 signaling pathway as part of its anti-CML properties. 
BCR-ABL1 exerts proleukemic actions by modulating additional 
signaling pathways, such as PI3K/AKT/mTOR and RAS/MAPK [4]. 
Notably, JKST6 inhibits the activation of the Src family of kinases, in 
contrast to IM, which is important due to the involvement of Src 
deregulated signaling in CML progression and TKI resistance [12]. 
Remarkably, JKST6 modulates MAPK signaling in CML cells, inducing 
transient activation of JNK, moderate inhibition of p38MAPK activation, 
and sustained phosphorylation of ERK1/2. Conversely, other NPQ-based 
derivatives and hybrids have been shown to downregulate ERK1/2 
phosphorylation concomitantly with their antiproliferative actions in 
CML cells [21,22,43]. However, it has also been described that 
pERK1/2T202/Y204 induction is related to activated apoptosis in human 
leukemia cells [59], which may explain the results observed with JKST6. 
Alternatively, JNK transient stimulation and pP38MAPKT180/Y182 
downregulation have already been reported to be associated with the 
antiproliferative effects of NPQ derivatives and hybrids in CML [21,22]. 
Interestingly, the BCR-ABL1/GBR-2 complex recruits and stimulates 
PI3K in CML cells, and subsequently, AKT and mTOR are activated and 
promote cell growth and survival [60]. mTOR signaling controls mRNA 
translation via its direct effector, the ribosomal protein S6 [60]. 
Furthermore, it has been reported that the constitutive activation of 
mTOR observed in several tumors can downregulate receptor tyrosine 
kinase signaling (e.g., IGF-IR) and, eventually, AKT activation as a 
negative feedback mechanism [61]. Interestingly, JKST6 potently and 
Fig. 9. JKST6 blocks the BCR-ABL1/STAT5 signaling pathway and downstream target effectors in IM-resistant cells.(A) Immunoblotting detection of 
phosphorylated and total levels of BCR-ABL1, BCR, STAT5, CrkL, c-MYC, and PIM1 and the presence of γH2AX in whole-cell extracts of AR230 (left panel) and 
AR230-R (right panel) cells treated with vehicle (VEH; 0.05% DMSO), JKST6 (3 µM) or imatinib (IM) (0.3 or 0.7 µM) for the indicated times. β-actin was used as a 
loading control. Figures are representative of two independent experiments. (B) Cell viability measured in AR230-R cells pretreated with VEH ( ) or JKST6 (3 µM, ) 
for 3 h prior to wash-out steps, followed by IM treatment (0.01–10 µM). Figures are representative of two independent experiments, each performed in triplicate. (C) 
mRNA expression analysis by qPCR of BCR-ABL1/STAT5 axis-target oncogenes (BCR; b3a2; PIM1, c-MYC and the housekeeper GAPDH) in IM-resistant (K562-R) cells. 
(D) SOCS2 mRNA expression analyzed in K562 (upper panel) and K562-R cells (lower panel) treated with VEH ( ), JKST6 (3 µM, ) or IM (1 µM, ) for the 
indicated times. Data are presented as the mean ± SEM of three independent experiments, each performed in duplicate. Statistical significance was assessed using 
one-way ANOVA with Bonferroni post hoc test. *P < 0.05; **P < 0.01; *** P < 0.001; ****P < 0.0001 versus VEH-treated cells. 
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rapidly inhibits S6 and increases pAKTT308/S473, effects that suggest that 
the compound might inhibit mTOR. However, whether JKST6 exerts 
rapamycin-like effects in CML and the relevance of these potential 
properties on its molecular mechanism of action require further 
research. 
TKI intolerance and IM resistance are current key challenges in CML 
therapy [8]. Therefore, one of the crucial aspects within the studied 
JKST6 properties has been its ability to potentiate the TKI effect and 
overcome IM resistance. JKST6 acts synergistically with IM, inhibiting 
cell proliferation and STAT5 activation in K562 cells, which is a prom-
ising finding because it opens an opportunity to reduce the effective dose 
of IM and, subsequently, the risk of long-term associated toxicity. In 
addition, JKST6 is highly effective in both AR230-R and K562-R cells, 
where IM resistance is mainly associated with increased BCR-ABL1 
expression [36] or overexpression of Src family kinases [62], respec-
tively. Similarly, JKST6 is highly effective on K562mycT315I cells, 
whose IM resistance is linked to a point mutation at the so-called gate-
keeper residue of BCR-ABL1 [11]. Importantly, this mutation confers 
resistance to not only IM but also second-generation BCR-ABL1 in-
hibitors such as dasatinib and nilotinib [63]. JKST6 inhibition of the 
BCR-ABL1/STAT5 signaling pathway in AR230-R cells supports the 
hypothesis that the compound maintains its mechanistic modulation 
against the hyperactivation of the oncogenic pathway, suggesting an 
important utility of JKST6 in an already established IM-resistance 
context. The efficacy of JKST6 on CML-resistant cells was further 
corroborated by the inhibition of MYC and PIM1 mRNA levels [4]. 
SOCS2, a ubiquitin ligase that negatively regulates the JAK-STAT 
pathway [64], has been described to be overexpressed in 
BCR-ABL1 + cells, and this expression could be downregulated by IM 
treatment. Moreover, refractory and relapse responses to IM are asso-
ciated with enhanced SOCS2 expression [65]. Accordingly, our results 
showed higher basal SOCS2 mRNA levels in IM-resistant cells than in 
IM-sensitive cells. Additionally, significant IM-induced downregulations 
of SOCS2 expression were detected in both cell lines, contrasting with 
the described IM inability to modulate SOCS2 in resistant cells. This 
difference could be a result of the different mechanism of resistance 
present in K562-R cells, which is related to Lyn overexpression. 
Conversely, JKST6 stimulated SOCS2 expression after 6 h of treatment 
in both K562-R and K562 cells, which might contribute to the negative 
regulation of BCR-ABL1/STAT5 signaling in these cells. In fact, SOCS2 
overexpression may play a role in the ubiquitination of BCR-ABL1 
induced by JKST6 treatment since the SOCS family participates in 
target protein degradation [66]. Interestingly, JKST6 is able to 
circumvent IM resistance in CML cells overexpressing BCR-ABL1, 
probably largely motivated by a reduction in oncokinase levels, which 
seems effective in restoring sensitivity to TKI treatment. 
5. Conclusions 
In summary, JKST6 possesses a combination of interesting properties 
that make it into a promising compound to further study in order to 
overcome the main CML therapy limitations. First, JKST6 efficiently 
reduces BCR-ABL1, preventing not only its constitutive activation but 
also its function as a “scaffold protein” that in turn modulates alternative 
survival pathways. Second, this effective feature of JKST6 activity is 
maintained in cells that are resistant to IM by BCR-ABL1-dependent or 
BCR-ABL1-independent mechanisms. Third and clinically relevant, 
JKST6 potentiates IM-induced antitumoral effects, suggesting that it 
could be considered in combinatorial therapy with TKIs in CML. 
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Conceptualization, Validation, Formal analysis, Investigation, Re-
sources, Data Curation, Writing - review & editing, Supervision, Project 
administration, Funding acquisition. Leandro Fernández-Pérez: 
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